QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
NASDAQ:CMPX

Compass Therapeutics (CMPX) Stock Forecast, Price & News

$1.87
-0.05 (-2.60%)
(As of 09/21/2023 ET)
Compare
Today's Range
$1.83
▼
$1.92
50-Day Range
$1.92
▼
$2.93
52-Week Range
$1.81
▼
$5.65
Volume
295,496 shs
Average Volume
419,261 shs
Market Capitalization
$238.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.05
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Compass Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
384.0% Upside
$9.05 Price Target
Short Interest
Bearish
5.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.38) to ($0.52) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

440th out of 961 stocks

Biological Products, Except Diagnostic Industry

67th out of 159 stocks

See Top Rated MarketRank™ Stocks Here

CMPX stock logo

About Compass Therapeutics (NASDAQ:CMPX) Stock

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.

CMPX Price History

CMPX Stock News Headlines

August 24, 2023 | finance.yahoo.com
Here's Why We're Not Too Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Situation
August 3, 2023 | msn.com
HC Wainwright & Co. Reiterates Compass Therapeutics (CMPX) Buy Recommendation
September 21, 2023 | Chaikin Analytics (Ad)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
August 3, 2023 | msn.com
Compass Therapeutics GAAP EPS of -$0.09
August 3, 2023 | finance.yahoo.com
Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
June 22, 2023 | msn.com
Compass Therapeutics added to Russell indexes
June 22, 2023 | finance.yahoo.com
Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes
June 22, 2023 | finance.yahoo.com
Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes
September 21, 2023 | Chaikin Analytics (Ad)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
June 1, 2023 | finance.yahoo.com
Compass Therapeutics to Participate in Upcoming Investor Events
May 10, 2023 | markets.businessinsider.com
SVB Securities Keeps Their Buy Rating on Compass Therapeutics (CMPX)
May 4, 2023 | msn.com
Compass Therapeutics: Q1 Earnings Insights
May 4, 2023 | finance.yahoo.com
Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
April 26, 2023 | finance.yahoo.com
Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ
April 25, 2023 | usnews.com
Frequently Asked Questions: U.S. News College Compass
April 19, 2023 | finance.yahoo.com
Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
April 13, 2023 | finance.yahoo.com
With 55% ownership of the shares, Compass Therapeutics, Inc. (NASDAQ:CMPX) is heavily dominated by institutional owners
March 28, 2023 | finance.yahoo.com
Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium
March 17, 2023 | seekingalpha.com
Compass Therapeutics GAAP EPS of -$0.10
March 17, 2023 | finance.yahoo.com
We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely
March 15, 2023 | finance.yahoo.com
Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 15, 2023 | seekingalpha.com
CMPX Compass Therapeutics, Inc.
February 2, 2023 | finance.yahoo.com
Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference
January 27, 2023 | msn.com
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
January 27, 2023 | markets.businessinsider.com
Expert Ratings for Compass Therapeutics
January 26, 2023 | yahoo.com
Co-Founder Thomas Schuetz Just Bought A Handful Of Shares In Compass Therapeutics, Inc. (NASDAQ:CMPX)
January 24, 2023 | msn.com
Compass Therapeutics added to Wedbush Best Ideas List on lead cancer candidate
See More Headlines
Receive CMPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Compass Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CMPX Company Calendar

Last Earnings
8/03/2023
Today
9/21/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CMPX
CUSIP
N/A
CIK
1738021
Web
www.compasstherapeutics.com
Phone
617-500-8099
Fax
N/A
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.05
High Stock Price Forecast
$10.30
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+376.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.37)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-39,220,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-26.62%
Return on Assets
-24.58%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
18.07
Quick Ratio
18.07

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.44 per share
Price / Book
1.32

Miscellaneous

Outstanding Shares
127,460,000
Free Float
89,221,000
Market Cap
$242.17 million
Optionable
Not Optionable
Beta
0.71
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Thomas J. Schuetz M.D. (Age 62)
    Ph.D., Co-Founder, CEO & Director
    Comp: $829.56k
  • Dr. Vered Bisker-Leib M.D. (Age 52)
    MBA, Ph.D., Pres & COO
    Comp: $806.43k
  • Mr. Neil L. Lerner CPA (Age 56)
    VP of Fin.
  • Mr. Jonathan Anderman J.D.
    VP, Head of Legal & Corp. Sec.
  • Anna Gifford
    Communications Mang.
  • Dr. Minori Rosales M.D. (Age 60)
    Ph.D., Sr. VP & Head of Clinical Devel.
  • Ms. Karin Herrera B.A.
    VP & Head of Clinical Operations
  • Dr. James Kranz Ph.D.
    VP and Head of Chemistry Manufacturing & Controls

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













CMPX Stock - Frequently Asked Questions

Should I buy or sell Compass Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Compass Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CMPX shares.
View CMPX analyst ratings or view top-rated stocks.

What is Compass Therapeutics' stock price forecast for 2023?

5 equities research analysts have issued 12-month price objectives for Compass Therapeutics' shares. Their CMPX share price forecasts range from $8.00 to $10.30. On average, they predict the company's share price to reach $9.05 in the next twelve months. This suggests a possible upside of 376.3% from the stock's current price.
View analysts price targets for CMPX or view top-rated stocks among Wall Street analysts.

How have CMPX shares performed in 2023?

Compass Therapeutics' stock was trading at $5.03 on January 1st, 2023. Since then, CMPX shares have decreased by 62.2% and is now trading at $1.90.
View the best growth stocks for 2023 here.

When is Compass Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our CMPX earnings forecast.

How were Compass Therapeutics' earnings last quarter?

Compass Therapeutics, Inc. (NASDAQ:CMPX) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.01.

When did Compass Therapeutics IPO?

(CMPX) raised $50 million in an initial public offering (IPO) on the week of November 16th 2020. The company issued 9,000,000 shares at $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel acted as the underwriters for the IPO and Raymond James was co-manager.

What is Compass Therapeutics' stock symbol?

Compass Therapeutics trades on the NASDAQ under the ticker symbol "CMPX."

Who are Compass Therapeutics' major shareholders?

Compass Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.73%), Braidwell LP (4.67%), Monashee Investment Management LLC (1.55%), Geode Capital Management LLC (1.42%), State Street Corp (1.37%) and Foresite Capital Management V LLC (1.04%). Insiders that own company stock include Carl L Gordon, Orbimed Advisors Llc, Thomas J Schuetz and Vered Bisker-Leib.
View institutional ownership trends.

How do I buy shares of Compass Therapeutics?

Shares of CMPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Compass Therapeutics' stock price today?

One share of CMPX stock can currently be purchased for approximately $1.90.

How much money does Compass Therapeutics make?

Compass Therapeutics (NASDAQ:CMPX) has a market capitalization of $242.17 million. The company earns $-39,220,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.

How can I contact Compass Therapeutics?

The official website for the company is www.compasstherapeutics.com. The company can be reached via phone at 617-500-8099 or via email at ir@compasstherapeutics.com.

This page (NASDAQ:CMPX) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -